
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) has received mixed reviews from various experts, highlighting both its strengths and concerns. Many praise the company for its solid performance in Asia and wealth management, coupled with a healthy dividend yield, making it an attractive income stock. However, some analysts express caution due to overvaluation, suggesting that MFC may be overbought, trading at over 2x book value with slow earnings growth of around 8-9%. While the stock is seen as a reasonable long-term holding, there are calls for potential buying opportunities during market pullbacks. The general sentiment reflects a wait-and-see approach given the mixed indicators and the overall health of the financial sector.
The short-seller raising the lawsuit is an old issue; he strongly doubts this lawsuit will hurt MFC. MFC is cheaper than its peers, trading at 8x. He sees 8% growth and dividend growth. Their only issue is their John Hancock purchase. They're growing in Asia. Won't hurt you long-term. Very cheap now. He likes it here.